207 related articles for article (PubMed ID: 1762684)
21. Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity.
Jenner P; Hall MD; Murugaiah K; Rupniak N; Theodorou A; Marsden CD
Biochem Pharmacol; 1982 Feb; 31(3):325-8. PubMed ID: 7200363
[TBL] [Abstract][Full Text] [Related]
22. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats.
Meller E
Psychopharmacology (Berl); 1982; 76(3):222-7. PubMed ID: 6808540
[TBL] [Abstract][Full Text] [Related]
23. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity.
Creese I; Burt DR; Snyder SH
Science; 1977 Aug; 197(4303):596-8. PubMed ID: 877576
[TBL] [Abstract][Full Text] [Related]
24. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
Pich EM; Benfenati F; Farabegoli C; Fuxe K; Meller E; Aronsson M; Goldstein M; Agnati LF
Brain Res; 1987 Dec; 435(1-2):147-52. PubMed ID: 2962698
[TBL] [Abstract][Full Text] [Related]
25. Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation.
Marin C; Chase TN
Eur J Pharmacol; 1993 Feb; 231(2):191-6. PubMed ID: 8095897
[TBL] [Abstract][Full Text] [Related]
26. High- and low-affinity states of striatal D2 receptors are not affected by 6-hydroxydopamine or chronic haloperidol treatment.
MacKenzie RG; Zigmond MJ
J Neurochem; 1984 Nov; 43(5):1310-8. PubMed ID: 6208330
[TBL] [Abstract][Full Text] [Related]
27. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
Marin C; Parashos SA; Kapitzoglou-Logothetis V; Peppe A; Chase TN
Pharmacol Biochem Behav; 1993 May; 45(1):195-200. PubMed ID: 8516358
[TBL] [Abstract][Full Text] [Related]
28. Electroconvulsive treatment and haloperidol: effects on pre- and postsynaptic dopamine receptors in rat brain.
Reches A; Wagner HR; Barkai AI; Jackson V; Yablonskaya-Alter E; Fahn S
Psychopharmacology (Berl); 1984; 83(2):155-8. PubMed ID: 6431465
[TBL] [Abstract][Full Text] [Related]
29. Effects of apomorphine on morphine analgesia during the state of dopaminergic supersensitivity after chronic treatment with haloperidol.
Kamata K; Ogawa K; Noma S; Kameyama T
J Pharmacobiodyn; 1986 Jan; 9(1):88-94. PubMed ID: 3712211
[TBL] [Abstract][Full Text] [Related]
30. Lithium dissociates haloperidol-induced behavioral supersensitivity from reduced dopac increase in rat striatum.
Meller E; Friedman E
Eur J Pharmacol; 1981 Nov; 76(1):25-9. PubMed ID: 7318921
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
[TBL] [Abstract][Full Text] [Related]
32. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.
Wilmot CA; Szczepanik AM
Brain Res; 1989 May; 487(2):288-98. PubMed ID: 2525063
[TBL] [Abstract][Full Text] [Related]
33. Kinetic analysis of central nervous system supersensitivity induced in rats by long-term haloperidol administration. I. pA2 determination.
Palermo-Neto J; Bernardi MM; Saban R
Pharmacology; 1984; 28(4):203-10. PubMed ID: 6539476
[TBL] [Abstract][Full Text] [Related]
34. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
Schröder U; Schröder H; Augustin W; Sabel BA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
[TBL] [Abstract][Full Text] [Related]
35. Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.
Ben-Shachar D; Pinhassi B; Youdim MB
Eur J Pharmacol; 1991 Sep; 202(2):177-83. PubMed ID: 1687031
[TBL] [Abstract][Full Text] [Related]
36. A dietary haloperidol regimen for inducing dopamine receptor supersensitivity in rats.
Frey JM; Morgan WW; Ticku MK; Huffman RD
Pharmacol Biochem Behav; 1987 Apr; 26(4):661-9. PubMed ID: 3602028
[TBL] [Abstract][Full Text] [Related]
37. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
38. Ascorbate antagonizes the behavioral effects of amphetamine by a central mechanism.
White LK; Carpenter M; Block M; Basse-Tomusk A; Gardiner TW; Rebec GV
Psychopharmacology (Berl); 1988; 94(2):284-7. PubMed ID: 2832869
[TBL] [Abstract][Full Text] [Related]
39. Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide.
Tecott LH; Kwong LL; Uhr S; Peroutka SJ
Biol Psychiatry; 1986 Oct; 21(12):1114-22. PubMed ID: 2428411
[TBL] [Abstract][Full Text] [Related]
40. Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment.
Agnati LF; Fuxe K; Benfenati F; Battistini N; Zini I; Toffano G
Neurosci Lett; 1983 Oct; 40(3):293-7. PubMed ID: 6646502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
